AVXL +600% undervalued sleeperEncouraging preliminary progress on their phase 2 schizophrenia drug has pushed the one year target to $40 currently at $5.65. Last breakout from this range in Jan 2021 resulted in a 350% surge in one week. There are few resistances ahead for consolidation at $8, 10, 14, 20.